Developing drugs for the ‘undruggable’

Protein-protein interactions (PPIs) are classically considered to be 'undruggable' targets. However, with up to 650,000 of them in the human interactome, they are an attractive option when considering novel therapeutic targets. By 2011, only approximately 2% of PPIs had been targeted with drugs. Over the last decade, PPIs have been turned to more and more for precision treatments of diseases in which therapeutic options are limited. They underpin many important cellular processes, however, they are difficult to study, thus have remained elusive and not fully understood. The potential for PPIs in discovering novel drug candidates is immense, however, novel screening...